Background: In November 2011, Malawi introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant schedule. Four to six years after introduction, rolling prospective nasopharyngeal carriage surveys were performed in the city of Blantyre. Carriage of Streptococcus pneumoniae vaccine serotypes (VT) remained higher than reported in developed countries, and VT impact was surprisingly asymmetric across age-groups with older individuals experiencing higher carriage reduction (35% for unvaccinated 8-9 years old, versus 26% for vaccinated 3-5 years old).
Introduction
Streptococcus pneumoniae (pneumococcus) is a bacterial human pathogen commonly carried asymptomatically in the nasopharynx, which in a minority of carriers can cause serious disease such as pneumonia, meningitis or bacteremia 1 , posing a serious mortality risk, especially for young children (<5 years of age), the elderly (>65 years of age) and the immunocompromised 2 . Pneumococcal carriage is a necessary precursor of severe disease 3 and transmission, such that reduction of carriage through active control is an important, universal public health goal.
Currently, pneumococcal conjugate vaccines (PCV) are the best available tool to reduce carriage and disease both within risk groups and the general population. These vaccines have consisted of either 7, 10 or 13 polysaccharides conjugated to a carrier protein (PCV7, PCV10, PCV13, respectively). All have been demonstrated to be highly protective against 7, 10 or 13 of the most common pneumococcal serotypes associated with carriage and disease (also termed vaccine serotypes, VT). A common consequence of PCV introduction is the increase in both carriage and disease of non-VT pneumococci (NVT), likely due to increased niche availability and reduction of competition between VT and NVT PCV routine vaccination has been a common control strategy for over a decade in developed countries, with past experience showing that both pre-and post-PCV pneumococcal carriage can be highly variable within and between countries [10] [11] [12] [13] [14] [15] [16] . PCV vaccines have only recently been introduced in Sub-Saharan African countries, of which Kenya 17, 18 , Malawi 19 , The Gambia 20 and South Africa 21 are examples. In November 2011, Malawi introduced the 13-valent pneumococcal conjugate vaccine (PCV13) as part of the national extended program of immunization with a 3+0 schedule (at 6, 10 and 14 weeks of age). With high routine coverage (>90%) and a small catch-up campaign of young children, PCV13 was expected to quickly reduce carriage as previously reported in developed countries. However, recently published data on nasopharyngeal carriage as measured in a cross-sectional observational study in Blantyre (Southern Malawi), four to six years after PCV13 introduction, shows that impact has been slower than expected and heterogeneous across age-groups 22 . Epidemiological mathematical models been employed successfully to improve our understanding of pneumococcal dynamics 5, 9, [23] [24] [25] [26] [27] , as well as having contributed to explain, estimate and project PCV impact 8, 11, 28 . The main advantage of models is their cost-free potential to test hypotheses and gain a mechanistic, ecological and immunological understanding of carriage and disease dynamics, estimating epidemiological parameters which are difficult to otherwise quantify from raw epidemiological data. For example, such models have yielded estimates of VT and non-VT pneumococci transmission potentials 26, [29] [30] [31] , pneumococcal competition factors 8, 9, 23, 28, 32, 33 and measures of PCV-induced protection from carriage at the individual level 11, 17, 28, 34, 35 , none of which are readily observed or quantified in cross-sectional observational studies.
In this study we use a Bayesian Markov-chain Monte Carlo fitting approach and a mathematical model to investigate the post-PCV13 introduction pneumococcal VT carriage dynamics in Blantyre. We find that natural immunity and age-specific transmission potentials are necessary to reproduce observed VT carriage. When compared to numerous literature reports from other regions, our estimated vaccine efficacy (individual-level protection from carriage) was close to expected, but impact (population-level reduction of VT carriage) was lower both in the short-and long-term. We show that hampered impact was likely due to a high local force of infection compared to other regions of the world. Our study offers key insights into the lower than expected PCV13 impact in Blantyre, and more generally on the heterogeneous nature of pre-and post-vaccination pneumoccocal VT carriage across age-groups and regions.
Methods Prospective cross-sectional observational study
An observational study using stratified random sampling was conducted to measure pneumococcal nasopharyngeal carriage in Blantyre, Malawi 22 . Sampling was performed twice a year for a total of 22.1 months, between June and August 2015 (survey 1), October 2015 and April 2016 (survey 2), May and October 2016 (survey 3), and finally November 2016 and April 2017 (survey 4). In this study, we use the mid-point dates of the surveys for model fitting and presentation of results. Nasopharyngeal swabs were collected from healthy, vaccinated 3-5 year old and unvaccinated 6-9 year old children, and processed following WHO recommendations 36 . Isolates were serotyped by latex agglutination (ImmuLex™ 7-10-13-valent Pneumotest; Statens Serum Institute, Denmark).
Observed VT carriage levels are presented in Figure 1d . Further details on collection, processing and observations, have been previously reported 22 .
Vaccine type transmission model
A deterministic, ordinary-differential equations (ODE) model (Figure 1a ) was developed to fit VT carriage levels as reported in the cross-sectional observational study in Blantyre (Figure 1d ) 22 .
Fitting was implemented using a Bayesian Markov chain Monte Carlo (bMCMC) approach developed and used by us in other modelling studies [37] [38] [39] , including informative priors for duration of carriage (Figure 1b ) and uninformative uniform priors for vaccine efficacy (individual-level protection against carriage) and transmission potential. The methodology is summarised in this section and further details such as equations and complementary results can be found in Supplementary Text.
Infection dynamics and population size
As depicted in Figure 1a , the population was divided into seven non-overlapping age-groups: 0 (<1), 1, 2, 3-5, 6-7, 8-9, 10+ years old. Ageing was approximated by moving individuals along agegroups with a rate (a age-group ) equal to the inverse of the time spent at each age class. The seven agegroups were further divided into vaccinated (S v age-group , C v age-group ) and unvaccinated (S age-group , C age-group ) susceptibles (S) and carriers (C). The population size was assumed to be constant, with total deaths equal to births (details in Supplementary Text). Death rates were age-specific (µ age-group ) and relative to a generalized total life-span of 70 years.
Natural immunity
Pneumococcal colonization increases both humoral (anti-capsular serotype-specific and anti-protein non-serotype-specific) and T-cell (anti-protein) immunity 40 . Acquisition of this immunity correlates with colonization in children and increases with age as colonization decreases. In our model, all individuals were assumed to be born susceptible but could acquire infection (colonization) at any age with a particular force of infection λage-group, becoming carriers (Cage-group) for an age-specific period (1/γγage-group), and returning to the susceptible state (Sage-group) after clearance. Hence, the development and accumulation of complete (sterile) immunity to the pneumococcus was not considered. We nonetheless allowed for decreasing duration of carriage with age (1/γγage-group) as a proxy for the development of immunity with age. To quantify such differences in age, we used carriage duration data as reported by Hogberg and colleagues 41 to define informative priors related to the aggregated age-groups: 0-2 years (1/γγ 0-2 ), 3-5 years (1/γγ 3-5 ), 6-8 years (1/γγ [6] [7] [8] , and 8+ years (1/γ γ 8+ ) as represented in Figure 1b .
Vaccination and vaccine efficacy
For simplicity, routine vaccination was implemented at birth with coverage (ρ) at 93% 22 , and catchup (k) implemented as a one-off transfer of a proportion of individuals from the unvaccinated susceptibles with 0 (<1) years of age (S 0 ) to the vaccinated susceptible class with the same age (S v 0 ) with coverage of 60% 22 . We assumed the vaccine to reduce the risk of infection (colonization) of vaccinated individuals by a proportion ζ (between 0 and 1, with ζ=1 equating to no risk). This reduction in risk was herein defined and interpreted as the individual-level vaccine efficacy against carriage (VE= 100 x ζ), and was modelled directly on the force of infection (λ) (Figure 1a ).
Vaccine impact
We measured vaccine impact across ages as the post-PCV13 percent reduction in population-level pneumococcal VT carriage compared to pre-vaccination levels.
Force of Infection
We used an inhomogeneous transmission matrix ( Figure 1c ) based on epidemiological studies conducted in American, European and African populations reporting strong, intrinsic variation in frequency, efficiency and environmental risk of transmission between age-groups 10, 31, [42] [43] [44] [45] [46] [47] . In summary, we defined an age-specific transmission matrix, generally populated with a baseline coefficient β, and a different coefficient θ assigned to transmission occurring within and between ages 0-5 years, and within 6-7 and 8-9 years of age. This formulation followed reports of strong age-assortative patterns and higher contribution of younger individuals to transmission 31, 43, 47 .
Fitting to survey data
The model's carriage outputs for vaccinated 3-5 (V3-5y), unvaccinated 6-7 (NV 6-7y) and 8-9 
Results

Observational study and modelling objectives
VT carriage levels as reported in the observational study (Figure 1d ), approximately four to six years after the introduction of PCV13 in Blantyre, showed a surprisingly slow mean reduction of 26% for the vaccinated 3-5 age-group (from 23%, CI 95% 17.9-27.1%, to 17%, CI 95% 13. 22 . In contrast, the mean observed reduction in VT carriage for the unvaccinated 6-7 agegroup was higher, at 31% (from 26%, CI 95% 20-31.9%, to 18%, CI 95% 12.2-22.1%) and for the unvaccinated 8-9 age-group it was even higher at 35% (from 20%, CI 95% 15.8-23.6%, to 13% CI 95% 9.3-17.4%). We hypothesised that the faster reduction in the older age groups was likely to be due in part to indirect protection through a reduction in transmission, as reported in other countries such as the USA and UK 48, 49 . We performed a literature review on observed reduction of VT carriage in time after the introduction of PCV13 vaccines (Table S4) , and concluded that residual 17% of VT carriage in the vaccinated 3-5 age-group, 6 years after PCV13 introduction, was high when compared to other countries. For instance, residual carriage of PCV13 types was 0.4% after 4 years of vaccination in England 50 , 9.1% after 2 years of vaccination in Italy 51 , and 7% after 3 years of vaccination in Alaska, USA 16 (more examples in Table S4 ).
We resorted to our deterministic transmission model and bMCMC approach to fit the observed postvaccination VT carriage data from Blantyre (2015 -2017). Based on this fit, we could reconstruct carriage dynamics for the unobserved first four years (2011 -2015) , and project VT carriage reduction into the future, to identify the mechanistic nature of the slow PCV13 impact on the vaccinated age-group and strong herd-effects in the older unvaccinated age-groups.
Model fit and posteriors
VT carriage levels across age-groups reported from the surveys were closely reproduced by the mean and 95% CI of the model using the bMCMC approach (Figure 2a ). Our initial assumption of natural immunity accumulating with age was generally respected in the bMCMC solution ( Figure  2b) ; i.e. the estimated posterior distributions of the durations of carriage (1/γγ age-group ) were similar to the informed priors for the groups 0-2 and 3-5 years of age, and were adjusted by the bMCMC by approximately +0.6 and -1.8 days for the groups 6-7 and 8+ years of age, respectively. The posterior distribution of vaccine efficacy (individual-level protection against carriage) across ages was estimated to be 68.8% (95% CI 41.6 -88.1). While we used an uninformative prior (uniform, 0 to 1) in the bMCMC, this posterior was similar to others recently estimated with different models and in multiple epidemiological settings ( Figure 2c) ; and we therefore argue that it serves as partial validation for the robustness of the modelling framework. Finally, the solutions for the transmission coefficients β and θ suggested that in order to reproduce the Blantyre survey data, the risk of infection associated with contacts within and between younger age-groups (0-5 years old) would have to be higher than that of the general population (i.e. θ>>β). Literature support for all estimated posteriors is detailed in Supplementary Text.
Vaccine impact across age-groups
Using parameter samples from the bMCMC estimated posteriors, we simulated vaccine impact in terms of VT carriage reduction across age-groups in the first 10 years post-vaccination (Figure 3 ).
After the first year, reduction in VT carriage was estimated to be 38% (23 -44, CI 95%) for the 0 (<1) years old, followed by 23% (15 -26, CI 95%) for the 1 years old, 12% (8 -13, CI 95%) for the 2 years old and 7% (5 -8, CI 95%) for 3-5 years old (Figure 3a dropped and vaccinated individuals aged, the older groups were estimated to benefit from increasingly similar reductions in carriage compared to the initially vaccinated group. Since during the first year only the 0 (<1) years of age were vaccinated, the short-term reductions in carriage of the other groups were due to indirect herd-effects alone.
At the target point of 10 years into the post-vaccination era, impact was estimated to be similar across all age-groups, with VT carriage reduced by 71% (CI 95% 42-81%) for the 0 (<1) years old, 69% (CI 95% 41-80%) for the 1 years old, 68% (CI 95% 42-80%) for the 2 years old and 69% (CI 95% 42-79%) for 3-5 years old. We further projected vaccine impact on aggregated age-groups 0-5 and 6-9 years of age, which showed equivalent reductions in VT carriage (Figure 3b) , with the larger aggregated age-group 0-9 years old having a reduction of 70% (CI 95% 41-82) after 10 years.
Post-vaccination changes in force of infection
The model had so far been able to reproduce survey data on VT carriage of vaccinated and unvaccinated individuals, with projections further suggesting that impact on older age-groups would be slower to gain momentum but would eventually converge to the observed impact on younger age-groups. To try to understand these non-linear and asynchronous responses to vaccination across age-groups, we explored the post-vaccination dynamics of the force of infection (FOI). The FOI is a useful epidemiological measure as it is the overall rate by which a certain age-group of susceptible individuals is infected, comprising the transmission rate (β or θ) weighted by the number of infectious individuals within the same and other age-groups.
Although we modelled six independent age-groups under 10 years of age, only three unique FOIs are defined in the transmission matrix for individuals under 9 years of age (0-5, 6-7 and 8-9 years of age, Figure 1c) . As expected by the posteriors of β and θ, the absolute FOI of these age-groups was originally different and decreased in time after the introduction of PCV13 ( Figure S4) . We looked at the FOI derivative in respect to time as a measure of speed of reduction (Figure 4) , and found that the time period of fastest FOI reduction for the 0-5 years old was between the years 2012 and 2014 (when no carriage data was collected), while for the older age-groups the period of fastest reduction was predicted to be just before or during the observational study (for 6-7 and 8-9 age-groups, respectively).
This temporal response suggested that although there is now a rather slow reduction of VT carriage in Blantyre for the younger age-groups, this seems to have been preceded by period of high, shortterm impact on VT carriage for that age-group (also seen in dynamics of Figure 3b) . Similarly, the surprisingly faster reduction in VT carriage observed during the surveys for the older age-groups is predicted by the model to take place specifically during the years of the surveys. Overall, projected FOI dynamics suggest that impact of the vaccine is non-linear in time within age-groups, with predicted periods of faster reductions in VT carriage being witnessed by different ages in a sequential manner, from younger to older individuals.
The projected impacts of Figures 3 and 4 were based on the estimated transmission coefficients for Blantyre (Figures 1c and 2d) . To contextualize this particular transmission setting, we searched the literature for pre-vaccination VT carriage levels in other countries (Table S5 ). The reported agegroups were highly variable, and we therefore focused on the 0-5 years old group for which more data points were available from a range of countries in North America, Africa, Europe and Southeast Asia (Figure 5a ). Reported VT carriage in this age-group was highly variable both between and within countries, with our estimation for Blantyre being on the higher end (62%, 95% CI 37 -76%).
We further searched the literature for post-vaccination VT carriage levels in other countries and again focused on the age-group 0-5 years old for which more data points were available (Table S4 , points with whiskers in Figure 5b ). The projected impact for Blantyre according to our model (dashed line), was notably lower than observed for other countries. A Malawi data point reported in the context of the Karonga District (Northern Malawi) had the closest impact to our projections in Blantyre (Southern Malawi), 4 to 5 years after PCV13 introduction 19 .
Given that our posterior of vaccine efficacy (individual-level protection against carriage, Figure 2c ) was close to estimations from other regions of the world, we hypothesised that both the higher preand post-PCV13 VT carriage levels in Blantyre were likely due to a higher local force of infection compared to other regions. To demonstrate this, we simulated a range of alternative transmission settings in Blantyre, by varying both the transmission coefficients (β and θ) between -70% and +120% of the estimated posteriors. This sensitivity exercise showed that lowering local transmission by -30% was sufficient for the model to appoximate short-and long-term vaccine impact observed in several other countries (Figure 5b ). Other age-groups, for which far less data points were available, presented similar patterns ( Figures S2 and S3 ).
Discussion
Using a dynamic model, we have reproduced observed changes in pneumococcal VT carriage following the introduction of PCV13 in Blantyre (Malawi). Similarly to other modelling frameworks we have considered the accumulation of natural immunity with age and have also allowed for heterogeneous transmission potentials within and between age-groups. Including these factors allowed us to characterise both vaccine-related and host age-dependent determinants of post-PCV13 pneumococcal VT transmission.
A main motivation for this study was the observation of high residual VT carriage levels six years post-PCV13 introduction 22 . Studies from Kenya, The Gambia and South Africa have reported similar trends, with VT carriage remaining higher than in industrialised countries at similar postvaccination time points. Compared to studies from other geographical regions (Figures 2c, 5a , 5b, Supplementary Material), pre-and post-vaccination VT carriage in Blantyre was at the upper end of reported values across many countries. Given that our estimate of vaccine efficacy (individual-level protection against carriage) was similar to reports from elsewhere, we tested the hypothesis that the observed and projected lower vaccine impact was likely a result of a higher force of infection in Blantyre compared to other regions. This force of infection was found to be characterised by different transmission potentials within and between age-groups, and particularly dominated by individuals younger than 5 years. Reflecting a variety of approaches and assumptions that can be found in other models 8, 11, 28 , our framework is not able to discern if this assortative relationship with age is due to age-specific contact type patterns or susceptibility to colonization. Nonetheless, our results strongly argue for the need of more research characterising local contact, risk and transmission-route profiles (e.g 42 ), if we are to understand the myriad of reported PCV impacts across different demographic, social and epidemiological settings.
There was also the unexpected observation that vaccine impact (reduction in carriage), four to six years post-PCV13, was higher in the older unvaccinated age-group. The dynamic model helped explain this, by showing that age-groups can experience periods of faster vaccine impact at different time points, from younger to older groups, as a likely consequence of routine vaccination at very early age, vaccinated cohort ageing and age-specific transmission potentials. Similarly to the conclusions of another modelling study 28 , our results thus advocate for the essential role of dynamic models to understand and project VT carriage, by critically accounting for local non-linear effects of pneumococcal transmission and vaccination.
Critical for developing countries, as well as global initiatives such as Gavi, is that the impact of PCVs on pneumococcal VT carriage and transmission needs to be further improved if we are to maximize disease reduction. For countries like Malawi, in which post-vaccine VT carriage data suggests that local epidemiological factors may dictate lower vaccine impact than elsewhere, region-specific improved vaccination schedules 19, 22 and catch-up campaigns 28 could help speed-up VT carriage reduction and maximise cost-effectiveness. For this to be possible, we need to better understand local transmission profiles across ages, which are likely dictated by demographic and socio-economic factors, and strongly determine short-and long-term PCV impact as demonstrated in the case of Blantyre.
Limitations
Data suggests that immune responses to PCV vaccines wane with time from vaccination 22, 34 . In a meta-analysis study, PCV7 efficacy was estimated at 62% (CI 95% 52-72%) at four months postvaccination, decreasing to 57% (CI 95% 50-65%) at six months, but remaining 42% (CI 95% 19-54%) at five years post-vaccination 34 . Models implicitly parametrising for duration of vaccineinduced protection (dVP) have typically followed a prior with minimum mean duration of six years 8, 11, 28, 34 , but in one study dVP was estimated as 8.3 years (95% CI 5 -20) 8 . Our framework does not explicitly include dVP. In the context of these reported time ranges, and since we fit data up to 6 years post vaccine introduction, further restricting our analyses to the first 10 years, we argue that our projections should be robust. In light of the possibility that dVP is shorter than previously reported 22 , our projections of vaccine impact should be seen as a best-case scenario; i.e. real longterm vaccine impact in Blantyre would likely be lower than projected by our model.
Our framework also does not include niche competition between VT and non-VT pneumococci 11, 28, 34 . It is difficult to assert the impact of such competition in our main results, but its unlikely that our main conclusions would be affected, since they are mostly based on factors (e.g. age-specific transmission) which have not been reported to be associated with type competition directly.
Conclusion
In Blantyre, vaccine efficacy (individual-level protection against carriage) across ages and time is estimated at 68.8% (95% CI 41.6 -88.1), similar to reports from other countries. However, local transmission potential is likely to be higher than in such countries, and also heterogeneous among age-groups, with a particular contribution from younger children. While PCV13 is achieving positive outcomes in Blantyre 19, 52 , such local higher force of infection is dictating a much lower long-term vaccine impact (population-level carriage reduction) than reported elsewhere. Finally, the combination of age-related transmission heterogeneities and routinely vaccinating infants has led to non-linear responses in terms of vaccine impact across ages and time, with general implications on post-vaccination VT carriage data interpretation. . Labels a age-group mark ageing rates per age class; µ age-group mark age-specific death rates; b marks births, at which point a proportion (ρ) are v ) are vaccinated (purple); ζ marks vaccineinduced protection, expressed as reduction in susceptibility to infection of vaccinated individuals (magenta); λ age-group mark age-specific forces of infection; γ age-group mark age-specific rates of clearance from infection; k marks catch-up vaccination (green). The postvaccination force of infection (FOI) of different age groups was calculated for each of 100,000 simulations using parameter samples from posteriors. For each FOI time series of each age-group, the time point of minimum derivative was calculated as a proxy for the time period of fastest FOI reduction, resulting in one distribution per age-group (coloured curves, 0-5 years of age in green, 6-7 in blue, 8-9 in red). The shaded areas are red for the pre-vaccination period, yellow for the postvaccination period with no carriage data, white for the post-vaccination period with survey carriage data, and grey for the post-vaccination projected period up to 10 years. The grey arrows mark the year of PCV13 introduction and years of the four surveys. Table S5 ). (b) The baseline transmission coefficient (β) is varied by considering the 70%, 60%, 50%, 40%, 30%, 20%, and 10% lower, and 10%, 20% higher transmission than the estimated for Blantyre (Malawi, β Malawi ) when fitting the observational study (e.g. 10% lower is 0.9*β Malawi ). The impact projections for the age-group 0-5 years old using the β estimated for Blantyre (Malawi) are presented by the dashed line (as in Figure 3b ). For visual purposes only the means are shown, obtained from simulations sampling 100,000 parameter values from posteriors. The symbols and whiskers are measures of reported impact (carriage reduction) and 95% CIs for several published studies (in legend, Table S4 ). The grey arrows mark the year of PCV13 introduction and the years of the four surveys. 
Figure legends
